As of 2025-06-13, the EV/EBITDA ratio of ANI Pharmaceuticals Inc (ANIP) is -50.08. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ANIP's latest enterprise value is 1,817.92 mil USD. ANIP's TTM EBITDA according to its financial statements is -36.30 mil USD. Dividing these 2 quantities gives us the above ANIP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 9.6x | 8.8x |
| Forward P/E multiples | 8.5x - 10.6x | 10.4x |
| Fair Price | (35.29) - (15.67) | (26.19) |
| Upside | -156.8% - -125.2% | -142.2% |
| Date | EV/EBITDA |
| 2025-06-10 | -50.53 |
| 2025-06-09 | -50.72 |
| 2025-06-06 | -49.99 |
| 2025-06-05 | -48.75 |
| 2025-06-04 | -49.34 |
| 2025-06-03 | -49.81 |
| 2025-06-02 | -49.96 |
| 2025-05-30 | -48.06 |
| 2025-05-29 | -47.78 |
| 2025-05-28 | -47.51 |
| 2025-05-27 | -47.82 |
| 2025-05-23 | -47.50 |
| 2025-05-22 | -47.19 |
| 2025-05-21 | -48.27 |
| 2025-05-20 | -49.20 |
| 2025-05-19 | -48.91 |
| 2025-05-16 | -48.81 |
| 2025-05-15 | -48.54 |
| 2025-05-14 | -49.04 |
| 2025-05-13 | -50.01 |
| 2025-05-12 | -50.19 |
| 2025-05-09 | -52.58 |
| 2025-05-08 | -55.70 |
| 2025-05-07 | -55.27 |
| 2025-05-06 | -54.94 |
| 2025-05-05 | -56.31 |
| 2025-05-02 | -56.54 |
| 2025-05-01 | -55.19 |
| 2025-04-30 | -55.27 |
| 2025-04-29 | -55.24 |
| 2025-04-28 | -55.23 |
| 2025-04-25 | -54.68 |
| 2025-04-24 | -54.57 |
| 2025-04-23 | -53.81 |
| 2025-04-22 | -54.16 |
| 2025-04-21 | -53.59 |
| 2025-04-17 | -54.31 |
| 2025-04-16 | -54.31 |
| 2025-04-15 | -54.51 |
| 2025-04-14 | -54.02 |
| 2025-04-11 | -53.66 |
| 2025-04-10 | -51.87 |
| 2025-04-09 | -52.40 |
| 2025-04-08 | -50.64 |
| 2025-04-07 | -52.99 |
| 2025-04-04 | -53.30 |
| 2025-04-03 | -53.76 |
| 2025-04-02 | -54.40 |
| 2025-04-01 | -53.60 |
| 2025-03-31 | -52.96 |